# DC Vaccination for Postremission Therapy in AML

> **NCT01734304** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 13 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** DC vaccination for postremission therapy in AML

## Key facts

- **NCT ID:** NCT01734304
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-05
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-09-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01734304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01734304, "DC Vaccination for Postremission Therapy in AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01734304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*